Navigation Links
Professor collaborates on most comprehensive analyses of NSAIDs and coxibs
Date:5/30/2013

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of the Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs (NSAIDs), which include cyclo-oxygenase-2 inhibitors (coxibs).

Hennekens and colleagues from around the world, under the direction of the Clinical Trial Service and Epidemiology Studies Unit at the University of Oxford, conducted a world-wide meta-analyses using individual participant data from 280 trials of NSAIDs vs. placebo and 474 trials of NSAID vs. another NSAID, which involved a total of 353,809 participants and a total of 233,798 person-years. These results address risks and benefits of drugs used for relief of inflammatory arthritis including cardiovascular disease and other relevant outcomes such as gastrointestinal effects.

"The vascular risks of high-dose diclofenac and ibuprofen are comparable to coxibs, while high-dose naproxen is associated with less vascular risk than other NSAIDs," said Hennekens. "Although NSAIDs increase vascular and gastrointestinal risks, their magnitude can be predicted, which may help guide clinical decision-making."

David J. Bjorkman, MD, MSPH, dean of the Charles E. Schmidt College of Medicine at FAU and a gastroenterologist noted that "these are the most comprehensive analyses ever conducted of the benefits and risks of NSAIDs, which include coxibs, and should help guide healthcare providers in their prescribing patterns."

Hennekens concluded that "from a clinical and policy perspective, the available data suggest that for relief of pain of inflammatory arthritis, naproxen may have the best benefit-to-risk ratio on cardiovascular disease (CVD). In contrast to naproxen, other traditional NSAIDS and coxibs confer similar moderately increased risks of CVD. At present, individual clinical judgments about coxibs and nonselective NSAIDs should not be limited to risks of CVD. They should also include concerns about non-CVD risks, such as gastrointestinal bleeding and other benefits, including improved quality of life resulting from decreases in impairment from musculoskeletal pain syndromes."

Science Watch ranked Hennekens as the third most widely cited medical researcher in the world from 1995-2005, and five of the top 20 were his former trainees and/or fellows. In addition, in 2012 Science Heroes, ranked Hennekens No. 81 in the history of the world for having saved more than 1.1 million lives.


'/>"/>

Contact: Gisele Galoustian
ggaloust@fau.edu
561-985-4615
Florida Atlantic University
Source:Eurekalert

Related medicine news :

1. Louisiana Tech University professor earns NSF Early Career Development grant
2. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
3. Louisiana Tech biomedical engineering professor earns recognition, funding for research
4. Women professorships low in some Scandinavian universities due to sexism
5. President Obama names SF State math professor a top young scientist
6. From textbook to flexbook: Professor uses new collaborative tool in the classroom
7. IHME professor named first health measurement winner of prestigious innovation award
8. Guys, take note: Male birth control pill may be ready soon, says Texas A&M professor
9. UBC professor wins Canadas top pharmaceutical research award
10. Huddersfield professors ground-breaking research shows just how well the 2012 Games were run
11. Grove Professor receives $1.5MM to study breast cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: